Matches in Wikidata for { <http://www.wikidata.org/entity/Q37864901> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q37864901 description "article científic" @default.
- Q37864901 description "article scientifique" @default.
- Q37864901 description "articolo scientifico" @default.
- Q37864901 description "artigo científico" @default.
- Q37864901 description "artículu científicu espublizáu n'abril de 2011" @default.
- Q37864901 description "bilimsel makale" @default.
- Q37864901 description "scientific article published on April 2011" @default.
- Q37864901 description "vedecký článok" @default.
- Q37864901 description "vetenskaplig artikel" @default.
- Q37864901 description "videnskabelig artikel" @default.
- Q37864901 description "vědecký článek" @default.
- Q37864901 description "wetenschappelijk artikel" @default.
- Q37864901 description "wissenschaftlicher Artikel" @default.
- Q37864901 description "наукова стаття, опублікована у квітні 2011" @default.
- Q37864901 description "научни чланак" @default.
- Q37864901 description "مقالة علمية نشرت في أبريل 2011" @default.
- Q37864901 name "Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer" @default.
- Q37864901 name "Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer" @default.
- Q37864901 type Item @default.
- Q37864901 label "Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer" @default.
- Q37864901 label "Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer" @default.
- Q37864901 prefLabel "Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer" @default.
- Q37864901 prefLabel "Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer" @default.
- Q37864901 P1433 Q37864901-818C96F6-FD30-483B-8B6B-0A3A646FA08A @default.
- Q37864901 P1476 Q37864901-F7D800EE-CD98-446B-BD41-4BE4013F1E3A @default.
- Q37864901 P2093 Q37864901-B4334BA4-E599-4F3E-B939-B93F3AF1550D @default.
- Q37864901 P304 Q37864901-1ADEBA00-430C-4C81-8F47-E83443371089 @default.
- Q37864901 P31 Q37864901-AE4F8678-4D9A-4972-B86F-154A28CBF9A3 @default.
- Q37864901 P31 Q37864901-e5530b49-0dd6-4428-a2f8-f05001ce5139 @default.
- Q37864901 P356 Q37864901-767581FC-1B68-4480-8491-34B6351C066F @default.
- Q37864901 P478 Q37864901-EF8C8289-05CA-422F-8C96-EE2BC6CA8A9D @default.
- Q37864901 P577 Q37864901-D2097DE3-2D97-4FD6-9363-709914F4E9B6 @default.
- Q37864901 P698 Q37864901-C8136AE3-BC64-4BAA-AE23-3FD5A81DDCAF @default.
- Q37864901 P921 Q37864901-9C7CCEB7-B807-4CDB-873E-72EC84DC0355 @default.
- Q37864901 P356 01.CCO.0000397417.75245.9C @default.
- Q37864901 P698 21490481 @default.
- Q37864901 P1433 Q1909046 @default.
- Q37864901 P1476 "Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer" @default.
- Q37864901 P2093 "Margarida Damasceno" @default.
- Q37864901 P304 "S3-9" @default.
- Q37864901 P31 Q13442814 @default.
- Q37864901 P31 Q7318358 @default.
- Q37864901 P356 "10.1097/01.CCO.0000397417.75245.9C" @default.
- Q37864901 P478 "23 Suppl" @default.
- Q37864901 P577 "2011-04-01T00:00:00Z" @default.
- Q37864901 P698 "21490481" @default.
- Q37864901 P921 Q413299 @default.